Trial Profile
Phase I/II study eribulin mesylate and lapatinib for metastatic in patients with human epidermal growth factor receptor 2-positive breast cancer previously treated with an anthracycline, taxane and trastuzumab
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Lapatinib (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2013 New trial record